Zoonotic Amebiasis: A Journey from Epidemiology to Treatment Strategy
Received Date: Apr 01, 2023 / Accepted Date: Apr 28, 2023 / Published Date: Apr 28, 2023
Abstract
The protozoan parasite Entamoeba histolytica is the cause of the disease known as amebiasis, which typically manifests as acute diarrhea, dysentery, amebic colitis, and amebic liver abscesses. E. histolytica is the fourth leading parasitic cause of human death. It mostly infects children in developing nations and is spread through contamination of food and water. Entamoeba sp. is present in the majority of infected individuals. Asymptomatically colonizes the large intestine and resolves on its own, whereas in others, the parasite can spread to soft organs and cause abscesses by breaching the mucosal epithelial barrier and causing amebic colitis. The treatment for invasive amebiasis that is both recommended and most commonly used is metronidazole (MTZ). Despite the fact that no amebiasis vaccine has yet been approved for human clinical trials, numerous recent vaccine development studies offer promise. For the counteraction and control of amebiasis, improvement of water cleansing frameworks and cleanliness practices could diminish illness frequency. The epidemiology, transmission, clinical signs, pathogenesis, diagnosis, treatment, prevention, and control of zoonotic amebiasis are the primary topics of this review.
Citation: Li X (2023) Zoonotic Amebiasis: A Journey from Epidemiology to Treatment Strategy. Air Water Borne Dis 12: 174. Doi: 10.4172/2167-7719.1000174
Copyright: © 2023 Li X. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
黑料网 Journals
Article Tools
Article Usage
- Total views: 1683
- [From(publication date): 0-2023 - Nov 22, 2024]
- Breakdown by view type
- HTML page views: 1547
- PDF downloads: 136